Application
of low concentrations (pu-nu) of NGF to mouse dorsal root ganglion (DRG)-spinal cord explants in long-term organotypic cultures rapidly prolongs the duration of the Ca2+-dependent component of the action potential (APD) in a major subset of DRG neurons that were previously shown to have characteristic responsiveness to exogenous opioids. These NGF-elicited excitatory modulating effects are blocked by pretreatment of the DRG neurons with monoclonal antibodies to rodent NGF receptors.
NGF-induced APD prolongation is also prevented by the opioid receptor antagonist naloxone and the specific K-opioid antagonist nor-binaltorphimine (but not by specific I(-and &opioid antagonists). The results suggest that NGF stimulates the release of endogenous opioids (e.g., dynorphin) from DRG neurons and that prolongation of the APD occurs secondarily by activation of excitatory K-opioid receptor functions on these same or nearby cells. NGF-induced release of small quantities of opioids by DRG neurons would be expected to prolong the APD in view of the remarkable sensitivity of these neurons to the excitatory effects of extremely low (fnn-nu) concentrations of exogenous opioid agonists. NGF-induced APD prolongation is blocked by the same cholera toxin A or B subunit treatments previously shown to block Gs coupling and GM1 ganglioside regulation of excitatory opioid receptors, respectively.
These in vitro studies suggest that excitatory opioid receptor-mediated functions may play a role in mediating some types of rapid NGF-induced hyperalgesic and other physiologic effects on the nervous system. [Key words: dorsal roof ganglion neuron, Ca2+ -dependent component of action potential, anti-NGF receptor antibody, specific opioid receptor antagonists, cholera toxin-sensitive excitatory opioid receptors] This laboratory previously showed that long-term treatment with NGF shortens the duration of the Ca*+-dependent component of the action potential (APD) of mature mouse dorsal root ganglion (DRG) neurons in culture when applied at concentrations of 0.3-30 nM for >2 d (Chalazonitis et al., 1987) . Conversely, application of anti-NGF antiserum to chronic NGFtreated DRG cells prolonged the APD to control values after > 1 d. In contrast to these slowly developing bioelectric effects, NGF has been shown to elicit much more rapid biochemical and structural changes in nerve cells (Greene and Shooter, 1980; Greene, 1984; Levi and Alema, 199 1) . For example, application of nM NGF to PC12 cells results in increased cytosolic Ca2+ concentration within minutes, due to enhanced Ca2+ influx as well as release from internal stores (Lazarovici et al., 1989) . Furthermore, nanomolar NGF increases the Ca2+-dependent release of dopamine and norepinephrine from PC 12 cells within a few minutes (Nikodijevic et al., 1990 ) and the release of histamine from mast cells within minutes in vitro in the presence of lysophosphatidyl serine (Bruni et al., 1982; Sugiyama et al., 1985; Mazurek et al., 1986) . In addition, NGF enhancement of endogenously released adenosine effects on PC12 cells (Race and Wagner, 1985) may account for previous reports that NGF rapidly stimulates CAMP levels in PC12 and other types of neurons (Nikodijevic et al., 1975; Schubert et al., 1978; Skaper et al., 1979) . In a recent review, Levi-Montalcini et al. (1990) reported that "following intravenous NGF administration, adult mice show a hyperalgesic response in a hot-plate test." This observation led us to test the hypothesis that NGF-induced hyperalgesia may be mediated by activation of NGF receptors on nociceptive types of DRG neurons that results in a rapid excitatory effect on these sensory cells. We previously showed that low concentrations of p-, 6-, or K-Opioid agonists (<nM) evoke excitatory APD-prolonging effects on many mouse DRG neurons in culture (Shen et al., 1989; Crain and Shen, 1990 ) by activating opioid receptors that are coupled via cholera toxin-sensitive Gs regulatory protein Crain, 1990a, 1994) to adenylate cyclase/cAMP/protein kinase A-dependent ionic conductances (Chen et al., 1988; Fan et al., 1991; Cruciani et al., 1993; Makman et al., 1994) . This is in contrast to the inhibitory shortening of the APD in DRG neurons elicited by higher (PM) concentrations of opioids that is mediated by opioid receptors that are linked via pertussis toxin-sensitive Gi/Go regulatory proteins (Shen and Crain, 1989; Gross et al., 1990) to other second messenger systems or directly to specific ion channels (Miyake et al., 1989) . Opioid-induced APD shortening in DRG perikarya has generally been considered to be a useful model of opioid analgesia mediated by inhibition of Ca*+ influx and transmitter release (e.g., substance P) at presynaptic terminals of primary afferent nociceptive neurons bearing inhibitory opioid receptors (Mudge et al., 1979; Werz and Macdonald, 1983; North, 1986; Shen and Crain, 1989; Crain and Shen, 1990) . Similarly, we have interpreted the delayed repolarization associated with APD prolongation that can often be evoked in the same DRG neuron perikarya by lower opioid concentrations as evidence of excitatory opioid receptor-mediated effects on these neurons. If similar increases in CaZ+ influx and transmitter release (e.g., substance P: Suarez-Rota and Maixner, 1993 ) also occur at the terminals of these DRG neurons, they "may mediate some of the paradoxical hyperalgesic and aversive side-effects of opioids in the central and peripheral nervous system" (Shen and Crain, 1989 ; see review by Crain and Shen, 1990) .
Application of low concentrations of NGF (PM-n@ to the same population of cultured DRG neurons that are responsive to exogenous opioids did, in fact, prolong the APD within a few minutes via activation of receptors that could be blocked by monoclonal antibodies to rodent NGF receptors. Surprisingly, NGF-induced prolongation of the APD was also prevented by the opioid receptor antagonist, naloxone, the specific K-Opioid receptor antagonist nor-binaltorphimine, as well as by other agents that block opioid-induced excitatory effects on DRG neurons (e.g., cholera toxin A and B subunits: Shen and Crain, 1990a,b) . These and related data suggest that NGF may stimulate the release of endogenous opioids (e.g., dynorphin) from DRG neurons that can then activate high-affinity excitatory K-opioid receptors on these cells, thereby resulting in APD prolongation.
A preliminary report of this study has been published (Shen and Crain, 1993) .
Materials and Methods
Tissue culture. Organotypic DRG-cord explants were prepared by dissecting transverse sections of spinal cord with attached DRGs from 13-d-old fetal mice (CD-l, Charles River). The explants were grown on collagen-coated coverslips in Maximow slide chambers and fed with Eagle's minimal essential medium supplemented with 25% fetal bovine serum, 10% chick embryo extract, 2 mM glutamine, 0.6% glucose and 10 mM HEPES buffer. During the first week in vitro the medium was supplemented with NGF (7s) at a concentration of 5 nM (-50 U/ml) to enhance survival and growth of the fetal mouse DRG neurons (Crain and Peterson, 1974; Crain, 1976; Chalazonitis and Crain, 1986) . Halfmaximal stimulation of initial neuritic outgrowth from these fetal DRG explants required about 0.1 nM NGF, but >90% of the DRG neurons degenerated within the first few days in vitro unless much higher concentrations of NGF were maintained during the first week after explantation Peterson, 1974, 1984) . Cultures were fed twice weekly and maintained at 34°C for electrophysiologic study after 3-7 weeks in vitro. For chronic treatment with K252a (200 nM), the drug was added to the nutrient medium of some of the cultures, beginning at 4 weeks in vitro, for 3-6 d.
Efectrophysiology. The culture coverslip was transferred to a small recording chamber containing about 1 ml of Hanks' balanced salt solution (BSS) supplemented with 4 mM Ca2+ and 5 mM Ba*+ (i.e., Ca/ Ba BSS). Addition of Ba2+ and high Ca2+ enhanced inward Ca2+ current, and BaZ+ suppressed delayed rectifying K+ current, thereby prolonging the Ca*t-dependent component of the action potential duration (APD) and providing a prominent baseline response for pharmacologic tests (Mudge et al., 1979; Werz and Macdonald, 1983; Chalazonitis and Grain; 1986; Chalazonitis et al., 1987; Shen and Crain, 1989) . The nresence of 5 mM Ba*+ areatlv enhanced the sensitivity of the DRG neurons to the excitatory-APD-prolonging effects of opioids (Shen and Crain, 1989; Crain and Shen, 1990) . HEPES (10 mM; pH 7.3) was used to replace the usual bicarbonate and phosphate buffers to prevent BaZ+ and Ca*+ precipitation. Intracellular recordings were made from DRG perikarya selected at random within each ganglion. The micropipettes were filled with 3 M KC1 (resistance -80-120 MO) and were connected via a chloridized silver wire to a neutralized input-capacity preamplifier (Axoclamp 2A) for current-clamp recording. After impalement of a DRG neuron, brief (2 msec) depolarizing current pulses were applied via the recording electrode to evoke action potentials (APs), at a frequency of 0.1 Hz. Recordings of the membrane resting potential (RP) and AP were stored on a floppy disk using the ~CLAMP program (Axon Instruments) in a microcomputer (IBM AT-compatible).
Drugs were applied by bath perfusion with a manually operated pushpull syringe system at a rate of 2-3 ml/min. Perfusion of NGF or other test agents was begun after the AP and RP of the neuron reached a stable condition during >4 min pretest periods in control Ca/Ba BSS. Tests were made on cells with RPs > 60mV. NGF-mediated chances in the APD were considered significant if the APD alteration was ; 10% of the control value. The APD was measured as the time between the peak of the APD and the inflection point on the repolarizing phase. Application of electric stimuli via a bridge-circuit precluded quantitation of possible NGF effects on the rate of rise of the AP. Since the APD varies with membrane RP, we generally applied a holding current manually to maintain the initially recorded RP at a slightly hyperpolarized level (--70mV) during the pharmacologic tests on each DRG neuron. This precluded systematic study of possible NGF-induced alterations in postspike hyperpolarization.
The following drugs (and their sources) were used in this study: NGF 7S (Collaborative Research); NGF 2.5s and rat anti-NGF-receptor (192-IgG, Boehringer Mannheim); K-252a (Calbiochem); adenosine deaminase, dynorphin A( 1-13) and D-Ala2,D-Let+enkephahn (DADLE) (Sigma); cholera toxin A subunit and B subunit (List); purified GM1 ganglioside (gift from Fidia); naloxone (Endo); (+)naloxone (NIDA); nor-binaltorphimine HCl, naltrindole HCl, p-funaltrexamine HCl (Research Biochemical). Stock solutions were prepared in distilled water (-1 mM) and stored frozen; 7S and 2.5s NGF were prepared in Eagle's minimal essential medium supplemented with 25% fetal bovine serum at concentrations of 100 &ml and aliquots were stored at -70°C and not refrozen after thawing. Cholera toxins were stored at 4°C. Cholera toxin-B subunit was heated to 56°C for 30 min to inactivate possible contamination with cholera toxin-A subunit (Shen and Crain, 1990b) . Stock solutions were diluted with the bath solution to desired test concentrations, discarding pipette tips after each successive lO-loo-fold dilution step to ensure accuracy ofextremely low (PM-fM) concentrations Crain and Shen, 1992) . In preparing test solutions of 7S and 2.5s NGF, the molecular weights of these preparations were considered to be 130,000 and 25,000, respectively.
Data analysis for determining significant differences was carried out with paired t test.
Results
In our previous studies, treatment of mouse DRG neurons with NGF 7S (0.3-30 nM) for >2 d resulted in a marked shortening (-30-60%) of the APD of these cells (Chalazonitis et al., 1987) , whereas no changes in the APD were observed in tests made after exposure to NGF for 34 hr. In the present study, electrophysiologic tests were carried out on similar long-term cultures of DRG-cord explants to determine if NGF could elicit much more rapid alterations in the APD of DRG neurons such as occur within minutes after acute application of opioids, monoamines, and other neurotransmitters (Mudge et al., 1979; Werz and Macdonald, 1983; Chalazonitis and Crain, 1986; Shen and Crain, 1989) . NGF rapidly prolongs the APD of opioid-sensitive DRG neurons. Intracellular recordings were made from small-and medium-sized DRG neuron perikarya (-10-30 pm in diameter) that generate relatively long APDs (> 3 msec in Ca*+/Ba*+ BSS) and that show characteristic responsiveness to opioid agonists (Shen and Crain, 1989; Crain and Shen, 1990 ; see introductory remarks). Acute application of selective inhibitory opioid receptor agonists (e.g., etorphine) to these DRG neurons shorten the APD in 80-90% of the cells tested, whereas low concentrations of bimodally acting (excitatory/inhibitory) opioids (e.g., morphine, dynorphin, enkephalins) prolong the APD in these same cells (Shen and Crain, 1994 6. Dyn(l-13) 1nM
7. BSS F&we I. NGF-evoked prolongation of the action potential duration (AED) of a cultured DRG neuron is blocked by pretreatment with antibodies to NGF receptors (anti-NGFR), whereas exogenous opioidevoked APD prolongation can still occur. I, AP generated by a DRG neuron in balanced salt solution containing 5 mM ?a>+ and 5 rnM Ba*+ (BSS) in response to brief (2 msec) depolarizing current pulse (same 2 msec stimulus used in all subsequent records). 2, APD is prolonged within 5 min after bath application of 0.1 nM NGF 7s. 3, After BSS rinse for 10 min and treatment with anti-NGFR (192-IgG, 5 &ml), APD returns to control value then stably maintained (-15 min) prior to additional tests. 4, Application of NGF (0.1 nM) in the presence of anti-NGFR is no longer effective in prolonging the APD (5 min test). 5 and 6, The same neuron shows no APD alteration during application of 1 tn.4 DADLE, but the APD is significantly prolonged by 1 nM dynorphin A( 1 -13). 7, After BSS rinse, APD shortens again. (Control tests indicated that anti-NGFR remains effective in blocking NGF-induced APD prolongation for > 1 hr after BSS rinse; see text.) Note that records in this and the subsequent figures are from DRG neurons in DRGspinal cord explants tested at 3-5 weeks in vitro. All acute tests were monitored for 5 min periods.
large DRG neurons (-30-50 pm in diameter) survive in our DRG-cord explants (-1 O-20%) and they show much shorter APDs (-l-2 msec), with no clear-cut inflection or "hump" on the falling phase of the spike (see Discussion). The APD of these large DRG neurons was not altered by exogenous opioids in our previous studies, or by NGF in the present study.
In contrast to the APD shortening observed after chronic NGF treatment of DRG neurons, acute application of similar and even much lower concentrations of NGF (7s or 2.5s) often elicited unexpected prolongation of the APD within a few minutes ( Fig. l ,,, 2A,,*). Both 7s and 2.5s NGF were effective at low concentrations in prolonging the APD of many DRG neurons by 20-120% (mean 68 f 6%, n = 99): in 78% of the cells tested at 0. l-l pM (n = 18; p < 0.00 1); in 88% of the cells tested at 10-100 PM (n = 58; p < 0.001); in 93% of the cells tested at l-10 nM (n = 41; p < 0.001). No significant evidence of NGFinduced APD shortening, nor alterations of the resting potential, was observed during these acute tests. The magnitude of the APD prolongation elicited by acute application of NGF did not show significant dose-dependent increases when tested at concentrations from 1 PM to 10 nM. The 2.5s form of NGF elicited similar effects on the APD as observed with the 7s form, except that the APD prolongation during sustained exposure to NGF-2.5s tended to attenuate more rapidly, often within 5 min. After washout of either form of NGF the APD generally returned to control values within 5-10 min, but in some cases recovery was much slower (> 15 min, e.g., A, vs A, in Fig. 2 ). These excitatory effects of NGF on DRG neurons were mediated by activation of NGF receptors since they were blocked after pretreatment of the cells with monoclonal antibodies to rodent NGF receptors , in five of five cells treated with 5 pg/ml anti-NGFR and in two of three cells with 50 rig/ml anti-NGFR (Fig. 13 ,J. Interestingly, the anti-NGFR used in the present study is directed against the "lowaffinity" ~75 NGF receptor (Chandler et al., 1984; see Discussion) .
Specific K-opioid receptor antagonists block NGF-inducedAPD prolongation. Since extremely low (f&r-nM) concentrations of bimodally acting opioids can rapidly prolong the APD of these nociceptive-like DRG neurons Crain and Shen, 1992a) , tests were carried out to evaluate possible opioid mediation of the NGF-induced APD prolongation. To our surprise, pretreatment of DRG neurons with naloxone (10 nM) prevented NGF-induced prolongation of the APD in 15 of 18 cells ( Fig. 2A,+) , whereas the inactive enantiomer (+)naloxone (10 nM) was ineffective in blocking NGF-induced APD prolongation of these cells (n = 4). The specificity of our anti-NGF receptor antibody preparation was controlled by tests showing that anti-NGFR (5 Kg/ml) did not block exogenous opioid-induced APD prolongation (tested with 1 nM dynorphin A( l-13) or DADLE; four of six cells; see also Fig. 15-7) . These results raise the possibility that NGF might stimulate the release of endogenous opioid from DRG neurons that in turn could activate excitatory opioid receptors (Crain and Shen, 1990) on the perikaryal surface of the same cells, thereby resulting in APD prolongation. This hypothesis was strengthened by additional tests with antagonists of specific p-, a-, and K-opioid receptors. Nor-binaltorphimine (10 nM), a specific K-antagOI& blocked NGF-induced APD prolongation in 10 of 12 DRG neurons (Fig.  2&J , whereas the p-and d-antagonists p-funaltrexamine and nalttindole (10-100 nM) were ineffective (n = 12) (Fig. 2B,,) . These pharmacologic tests suggest that NGF may prolong the APD of DRG neurons by stimulating release of specific endogenous opioids that could subsequently activate high-affinity excitatory K-opioid receptors on these cells. The presence of functional excitatory K-opioid receptors on DRG neurons showing NGF-induced APD prolongation was also demonstrated by the APD-prolonging effects evoked in the same cells after washout of NGF and application of exogenous dynorphin (e.g., Fig. 1 5-7) .
The Journal of Neuroscience, September 1994, f4 (9) NGF-induced release of endogenous adenosine from PC1 2 cells has been shown to mediate previously reported NGF-induced increases in CAMP by activating Gs-coupled adenosine receptors on these cells (Race and Wagner, 1985) . In the presence of adenosine deaminase, NGF failed to increase CAMP in PC 12 cells. Application of the adenosine analog, 2-chloro-adenosine to rat DRG neurons in culture has been shown to enhance forskolin-stimulated adenylate cyclase activity, presumably by activating Gs-coupled adenosine A, receptors on these cells (Dolphin et al., 1986) and preliminary tests indicate that adenosine elicits dose-dependent prolongation of the APD of mouse DRG neurons (Shen and Crain, unpublished observations) . However, acute application of NGF (0.1 nM) to DRG neurons in the presence of similar concentrations of adenosine deaminase (1 U/ml) still prolonged the APD by 25-100% in four of five cells. Therefore, NGF-induced APD prolongation in DRG neurons does not appear to involve release of endogenous adenosine.
Treatment of DRG neurons with cholera toxin A or B subunit blocks NGF-induced opioid-mediated APD prolongation. Further evidence consonant with mediation of NGF-induced APD prolongation by secondarily activated excitatory opioid receptors was obtained by pretreating the cells with cholera toxin-A subunit (CTX-A) and cholera toxin-B subunit (CTX-B). We previously showed that APD prolongation elicited in DRG neurons by application of low (<no) concentrations of exogenous opioid agonists could be prevented by pretreatment with CTX-A (which interfered with Gs coupling of these excitatory opioid receptors to adenylate cyclase: Shen and Crain, 1990a) A l.2, APD of a DRG neuron is prolonged by application of 0.1 nM NGF (as in Fig. 1 ,,*) . A,, After BSS rinse and introduction of 10 nM NLX, APD shortens and is then stably maintained (-15 min) prior to additional tests. A,, Application of 0.1 nM NGF in the presence of NLX is no lonaer effective in prolonging the APD. BL2, In contrast, application of NGF (1 nM) to another DRG neuron in the presence of the 6-opioid antagonist, naltrindole (NTI; 10 nM, 7 min pretreatment), is still effective in prolonging the APD. B,,,, The p-opioid antagonist B-funaltrexamine (B-FNA; 10 nM, 10 min pretreatment) is also ineffective in blocking the NGFinduced APD prolongation of this neuron. B,,, However, in the presence of the K-opioid antagonist nor-BNI (10 no, 10 min pretreatment), 1 nM NGF is no longer able to prolong the APD of this same neuron.
CTX-B (which interfered with GM1 ganglioside regulation of these receptors: Shen and Crain, 1990b; Shen et al., 1991) . In the present study, pretreatment of DRG neurons with CTX-A (0.1 &ml; > 15 min) blocked NGF-induced APD prolongation (12 of 12 cells; Fig. 3A ), just as it blocks exogenous opioidinduced excitatory effects (Shen and Crain, 1990a) . Similarly, pretreatment of DRG neurons with CTX-B (0.1 &ml; > 15 min) also blocked NGF-induced prolongation (six of six cells; Fig. 3B ), just as it blocks exogenous opioid-induced excitatory effects (Shen and Crain, 1990b) . These blocking effects of CTX-A and CTX-B were reversible after > 1 hr washout in BSS; NGF could then prolong the APD of other DRG neurons in the same explant.
GM1 ganglioside restores NGF-induced APD prolongation in DRG neurons after blockade by anti-NGFR treatment. We previously showed that brief treatment of DRG neurons with GM 1 ganglioside markedly reduced the threshold concentration of dynorphin A( 1-13) and morphine required to prolong the APD from 1 nM down to 1 fM (Shen et al., 199 1) . In the present study, similar treatment of DRG neurons with 1 KM GM 1 ganglioside after blocking NGF-induced APD prolongation with anti-NGFR (0.5-5 /Is/ml) resulted in rapid restoration of NGF-induced excitatory effects. These results can be accounted for by the increased efficacy of GM 1 -sensitized excitatory opioid receptors in responding to the much lower quantities of opioids that may be released from anti-NGFR-treated cells. However, our data do not preclude direct GM 1 ganglioside enhancement of NGFinduced release of opioids from DRG neurons that were incompletely blocked by anti-NGFR. The kinase inhibitor K-252a does not interfere with NGFinducedAPDprolongation. The kinase inhibitor K-252a is known to inhibit selectively many of the effects of NGF on DRG neurons (Matsuda and Fukada, 1988; Doherty and Walsh, 1989) and PC12 cells (Koizumi et al., 1988; Lazarovici et al., 1989; Ferrari et al., 1992) . Tests were therefore carried out to deter- Discussion tagonist naloxone. On the other hand, anti-NGF receptor antibody treatment did not block APD prolongation elicited by exogenous opioids. These results suggest that NGF may directly stimulate the release of endogenous opioid from DRG neurons and that prolongation of the APD occurs secondarily by activation of high-affinity excitatory opioid receptor functions on these same or nearby cells. Our data do not preclude, however, the possibility that small amounts of opioid may be tonically released from DRG neurons that do not reach threshold levels for evoking excitatory opioid receptor-mediated APD prolongation unless their effects are enhanced by a synergistic NGFinduced stimulatory effect on the Gs-coupled opioid second messenger system. The effectiveness of 0. l-l PM concentrations of NGF in prolonging the APD of about 80% of the DRG neurons tested in the present study is consonant with evidence that -2 PM NGF is required for half-maximal stimulation of neurite outgrowth or for cell survival in assays of chick embryo DRG neurons in Mediation of NGF-induced APD prolongation in DRG neurons culture (Sutter et al., 1979; Meakin and Shooter, 1992) anti-NGFR (192-IgG) that blocks these excitatory effects is directed against the low-affinity ~75~~~ (see below). Role of "low-a&ity"p75 NGF receptors in mediating NGFinducedAPDprolongation.
The present study shows that monoclonal antibodies to rat NGF receptors (192-IgG) that bind to "low-affinity" p75 NGF receptors (Chandler et al., 1984 ; Weskamp and Reichardt, 199 1) block NGF-induced APD prolongation of DRG neurons. These results are consonant with evidence that this antibody markedly decreases NGF-stimulated neuritic outgrowth from PC 12 cells (Chandler et al., 1984) and NGF-stimulated elevation of c-fos mRNA in PC 12 cells (Milbrandt, 1986) . Furthermore, injection of 192-IgG into fetal rats results in destruction of DRG and sympathetic neurons (Johnson et al., 1989) . Affinity cross-linking and gene transfer experiments support a model in which the low-affinity ~75~~~~ and high-affinity ~140"~ receptors participate in the formation of the high-affinity NGF receptor complex that mediates transmembrane signaling (Berg et al., 199 1; Hempstead et al., 199 1; Meakin and Shooter, 199 1; Weskamp and Reichardt, 199 1; Yan et al., 199 1; see also Green and Greene, 1986; Levi and Alema, 199 1) . This model may account for the blocking action of anti-NGFR (192-IgG) on NGF-induced APD prolongation in DRG neurons and other biological effects noted above.
Possible NGF-induced release of opioids from DRG neurons that activate K-t?xcitatory opioid receptor functions. NGF-induced prolongation of the APD is blocked by the specific K-Opioid receptor antagonist, nor-binaltorphimine, whereas the specific M-and d-opioid receptor antagonists, p-funaltrexamine and naltrindole were ineffective. These pharmacologic analyses suggest that NGF may stimulate the release of an opioid that selectively activates K excitatory opioid receptor functions. Our electrophysiologic results are remarkably consonant with radioimmunological and immunohistochemical studies demonstrating that significant concentrations of opioid peptides, especially the K-opioid, dynorphin, are present in many sensory ganglion neurons (Botticelli et al., 1981; Chalazonitis et al., 1984) , both in perikarya (Sweetnam et al., 1982 (Sweetnam et al., , 1986 Weihe et al., 1985 Weihe et al., , 1988a as well as in axons, dorsal roots, and peripheral terminals (Weihe et al., 1985; Basbaum et al., 1986) . Interestingly, previous studies have shown that systemically applied NGF induced an enhanced secretion of p-endorphin, ACTH, and corticosterone in vivo (Otten, 1984) .
Sensory neurons have been shown to release substance P in response to noxious stimuli in vivo (Jesse11 and Iversen, 1977; Helme et al., 1986; Duggan et al., 1987) and during electrical, high K+-or PGE,-stimulation in culture (Mudge et al., 1979; Holz et al., 1988; Nicol et al., 1992) . However, no evidence of the release of opioids from sensory DRG neurons has been reported. In order to obtain more direct evidence that NGFinduced APD prolongation is mediated by NGF-stimulated release of opioids, we have tested the perfusate collected from DRG-cord explants after exposure to NGF (0.1 nM, 5 min). Preliminary tests indicated that this perfusate could, indeed, prolong the APD of anti-NGFR-treated DRG neurons. These data provide further support for our hypothesis, but more systematic electrophysiologic and biochemical assays of the perfusates from NGF-treated DRG neurons are required to determine the quantities and specific molecular moieties of opioids that may be released from these DRG cells.
DRG neurons as a model system for in vitro studies ofprimary afferent nociceptor functions. As noted above, 80-90% of the DRG neurons in our long-term DRG-cord explant cultures generate a relatively prolonged APD with a characteristic "hump" on the falling phase of the AP. This hump results from the delayed onset of a voltage-dependent Ca2+ current following the Na+ spike that can be markedly shortened or prolonged in duration by specific opioid treatments (see introductory remarks; Mudge et al., 1979; Werz and Macdonald, 1983; Chalazonitis and Crain, 1986; Crain, 1989, 1994) . The prolonged APD + hump response of some of the DRG neurons in longterm culture may be due simply to their maintenance in vitro of this type of immature action potential mechanism (Scott and Edwards, 1980) that is characteristic of most rodent DRG cells at birth but is converted to a short APD without hump in large A-type neurons, but not small C-type cells, during maturation in vivo Yoshida and Matsuda, 1979; Fulton, 1987) and in long-term culture ; see also Chalazonitis and Crain, 1986) . On the other hand, the prolonged APD + hump response has been shown to be a characteristic property of nociceptive DRG neurons even after maturation in the adult rat (Ritter and Mendell, 1992) . This raises the possibility that the large population of small-and mediumsized DRG neurons (1 O-30 Frn in diameter) that continue to show similar prolonged APD + hump responses and opioid responsiveness after many weeks of maturation in long-term culture may provide a useful in vitro model system for analyses of primary afferent nociceptor functions in vivo.
The maturation of these DRG neurons in long-term organotypic explant cultures is evidenced by their progressive development of high levels of opioid receptors in the perikaryal and neuritic outgrowth regions during the first few weeks in vitro (Hiller et al., 1978) and their ability to develop functional opioidsensitive synaptic networks with spinal cord neurons in the dorsal-horn regions of the explants Peterson, 1974, 1982; Crain, 1976 Crain, , 1983 . DRG-evoked dorsal horn synaptic network responses in these explants are selectively attenuated by specific opioid agonists at concentrations that correlate well with their analgesic potency in vivo (Crain et al., 1977 . Furthermore, the much greater potency of etorphine vs morphine in shortening the APD of the DRG neurons in these explants (Shen and Crain, 1994) correlates remarkably well with the lOOO-fold greater analgesic potency of etorphine in vivo. These opioid-sensitive properties of DRG neurons in culture are, therefore, quite consonant with the selective inhibitory effects of opioids on nociceptive, but not proprioceptive, primary afferent neurons in vivo.
The excitatory effects of bradykinin, capsaicin, and prostaglandin E, (Baccaglini and Hogan, 1983; Pitchford and Levine, 1991; Nicol et al., 1992) on many DRG neurons in culture provide additional evidence indicating maintenance of nociceptor functions in vitro. Interestingly, capsaicin, which selectively activates nociceptive DRG neurons in vivo and in culture (Pitchford and Levine, 199 l) , has recently been shown to attenuate the anti-nociceptive effects of systemic morphine by releasing excitatory amounts of dynorphin in the spinal cord following intrathecal injection of low doses of capsaicin in adult mice . This selective excitatory effect of capsaicin-stimulated dynorphin on nociceptive input into the spinal cord, which is blocked by naloxone and nor-binaltorphimine, strengthens our hypothesis that NGF elicits excitatory K-opioidmediated effects on nociceptive types of DRG neurons (see also anti-analgesic effects of dynorphin by Fujimoto and Rady, 1989, noted below) . Ritter and Mendell (1992) showed that chronic treatment of newborn rats with NGF for 5 weeks in vivo resulted in a selective prolongation of the APD of nociceptive, but not proprioceptive, DRG neurons (identified by the characteristic long APD + hump criterion noted above). The mechanism of action of NGF in eliciting APD prolongation of nociceptive DRG neurons after chronic treatment in vivo is probably more complex than that mediating the rapid NGF-induced APD prolongation observed in cultured DRG neurons in the present study (see below). Nevertheless, these correlative data add further support to the view that the NGF-sensitive population of DRG neurons in our cultures show significant functional similarities to NGF-sensitive nociceptive DRG neurons in vivo.
The preponderance of DRG neurons that are sensitive to NGF and opioids in our long-term explant cultures may be due to preferential rescue of small, nociceptive DRG cells at immature stages, when they are dependent for survival on NGF (LeviMontalcini, 1965) , by NGF treatment during the first week in culture Peterson, 1974, 1984; Crain, 1976; see Materials and Methods) . These in vitro results are similar to the selective rescue of small-diameter nociceptive DRG neurons, but not large proprioceptive neurons, by injections of NGF in newborn rats after nerve section (Miyata et al., 1986) . In the absence of NGF treatment, >90% of the fetal DRG neurons degenerate during the first few days in culture, resembling the selective loss of 80-90% of small nociceptive-type DRG cells with unmyelinated axons following NGF-deprivation in utero (Johnson et al., 1980 Goedert et al., 1984; Otten, 1984) . These factors may account for the higher proportion of NGFsensitive DRG neurons, -8O-90% in our long-term cultures, in contrast to the distribution of high-affinity NGF receptors on 40-45% of adult rat DRG neurons (Richardson et al., 1986; Verge et al., 1989b) . The relatively sparse population of large DRG neurons that generate short APDs in our long-term cultures may be due to their preferential dependence on skin and muscle target tissues (Levi-Montalcini, 1966) which are absent in these cultures or to inadequate levels of growth factors other than NGF that may be required by proprioceptive types of DRG neurons.
Relevance ofNGF-inducedAPDprolongation in DRG neurons in culture to NGF-induced hyperalgesia in vivo. Our electrophysiologic evidence of rapid NGF-induced opioid-mediated excitatory effects on "nociceptive"-like DRG neurons in culture may clarify cellular mechanisms underlying the hyperalgesia observed after intravenous administration of NGF in adult mice (Levi-Montalcini et al., 1990 ) and the heat hyperalgesia that has recently been shown to occur within IO min after injection of NGF (1 &gm, i.p.) in adult rats . The relevance of opioid-induced excitatory prolongation of the APD of DRG neurons in culture to hyperalgesia in vivo is further suggested by studies with an animal model of persistent pain in arthritic rats where "exceedingly low doses of morphine. . . elicit a naloxone-reversible paradoxical hyperalgesia" (Kayser et al., 1987) . In addition, evidence has been reported of naloxonereversible hyperalgesia mediated by activation of K-opioid receptors on neurons in the brainstem and cervical spinal cord (Wu et al., 1983; Hamann and Martin, 1992; Parvini et al., 1993) . These hyperalgesic effects may be due in part, to enhanced release of substance P, which has been shown to occur following activation of K-opioid excitatory receptors on rat trigeminal neurons (Suarez-Rota and Maixner, 1993) . The excitatory effect of low concentrations of dynorphin and other K-Opioids on DRG neurons is also consonant with in vivo studies demonstrating that extremely low intrathecal doses of dynorphin (-0.05 fmol) in adult mice can attenuate the anti-nociceptive effects of systemic morphine (Fujimoto and Rady, 1989) . This anti-analgesic excitatory effect of dynorphin can be blocked not only by the opioid receptor antagonists naloxone and norbinaltorphimine, but also by intrathecal administration of cholera toxin Arts et al., 1993) .
If NGF-induced hyperalgesia in vivo is indeed mediated by activation of K excitatory opioid receptors on nociceptive neurons and can be prevented simply by coadministration of an opioid antagonist, the results of the present study may help to eliminate this undesirable side effect during clinical use of exogenous NGF for treatment of taxol-induced (Apfel et al., 199 1) and diabetic (Apfel et al., 1992) sensory neuropathies as well as other neurologic disorders (Marz, 1990) . Stimulated by our evidence that NGF-induced excitatory effects on DRG neurons are mediated by activation of K-Opioid receptors, Apfel et al. (1993) have shown that NGF-induced hyperalgesia in adult mice and rats can indeed be prevented not only by naloxone but also by nor-binaltorphimine, precisely as predicted by the present tissue culture study.
NGF-induced prolongation of the APD in the perikarya of "nociceptive"-like DRG neurons in culture provides a mechanism that may account for NGF-induced increases in Ca*+ influx and excitability at peripheral as well as central terminals of primary afferent nociceptors in vivo. Lewin et al (1993) have suggested that it is unlikely that NGF could gain direct access to the CNS when administered systemically in adult animals, so that the rapid onset of NGF-induced heat hyperalgesia is probably due to sensitization of the receptors of peripheral unmyelinated afferents to heat. This is consonant with evidence that NGF receptors (Verge et al., 1989a; Di Stefano et al., 1992) as well as opioid receptors (Hiller et al., 1978; Fields et al., 1980; Basbaum and Levine, 199 1; Levine et al., 1993) are distributed on peripheral as well as central branches of DRG neurons.
The present in vitro study may also provide insight into a possible physiologic role for dynorphin in sensory neurons in mediating NGF-induced nociceptive or "alerting" signals into the CNS during neural injury (Bakhit et al., 1991; MartinezMurillo et al., 1993) or other conditions where NGF levels are acutely elevated, for example, aggressive and defensive behavior (Aloe et al., 1986; Levi-Montalcini et al., 1990 ). Blockade of NGF-induced APD prolongation by CTX-A or CTX-B and enhancement by GM1 ganglioside may be due to effects on opioid-rather than NGF-receptorfunctions.
The blockade of NGF-induced prolongation of the APD of DRG neurons by low concentrations of CTX-A as well as CTX-B initially suggested possible Gs-coupling and GM 1 ganglioside regulation of the NGF receptors mediating these excitatory effects. However, it is more likely that these results are due to the blocking effects of CTX-A and CTX-B on the secondarily activated excitatory opioid receptor functions, similar to the actions ofthese toxin components in preventing exogenous opioid-induced APD prolongation (Shen and Crain, 1990a,b) . Furthermore, no evidence of direct NGF receptor coupling to Gs or Gi has been detected (Levi and Alema, 199 1) .
Although the kinase inhibitor K-252a selectively inhibits many of the effects of NGF on PC12 cells (Koizumi et al., 1988) it did not antagonize NGF-induced release of dopamine and norepinephrine from these cells and, in fact, mimicked this action of NGF on PC 12 cells (Nikodijevic et al., 1990) . Furthermore, although K-252a blocked NGF-induced survival of chick em-bryo sympathetic neurons in culture, it did not interfere with NGF-mediated survival of chick embryo DRG neurons grown under the same culture conditions (Borasio, 1990) . Therefore, the absence of blocking effects by K-252a on NGF-induced APD prolongation must be interpreted with caution. If K-252a does, in fact, block the rapid NGF-induced increase in intracellular calcium in DRG neurons as occurs in PC 12 cells (Lazarovici et al., 1989) , these results suggest that NGF-induced opioid release may not require a large increase in intracellular Ca2+ concentration (as also observed during studies of NGF-induced histamine release in mast cells: Mazurek et al., 1986) . Furthermore, since introduction of exogenous ganglioside can overcome the inhibitory effects of K-252a on NGF-induced neurite outgrowth in PC12 cells (Ferrari et al., 1992) perhaps the endogenous levels of ganglioside in these cells may also play a role in determining their sensitivity to K-252a inhibition of transmitter release. In the present study, however, elevation of GM1 ganglioside may restore NGF-induced APD prolongation in anti-NGFR-treated DRG neurons by greatly increasing the efficacy of opioidexcitatory receptor functions @hen et al., 199 1) elicited by activation of a small population of unblocked NGF receptors, rather than by a direct action of GM1 on NGF receptors.
Alterations of the APD ofDRG neurons after chronic treatment with NGF. As noted above, chronic exposure of mature DRG neurons in organotypic explant cultures to NGF for > 2 d results in shortening of the APD (Chalazonitis et al., 1987) . The mechanism underlying this long-term effect of NGF on the AP of DRG neurons is unknown. Perhaps it is due to a compensatory metabolic process that develops in these DRG cells that counteracts the initial NGF-induced excitatory APD prolongation observed in the present study. This shortening of the APD of DRG neurons during a >2 d exposure to NGF occurs in populations of cells that have become stabilized after 34 weeks in control culture medium and show no significant morphological alterations during the NGF test period. On the other hand, chronic injections of newborn rats with NGF for 5 weeks resulted in a small but significant increase in the APD of nociceptive DRG neurons (Ritter and Mendell, 1992) . However, this long-term effect may be due to complex developmental alterations in the properties of neonatal DRG cells in vivo involving mechanisms that may be quite different than those mediating the APD modulation elicited by NGF within a few minutes or a few days after application to relatively mature DRG neurons in culture.
Concluding remarks. The experimental paradigm used in the present study provides a sensitive electrophysiologic tissue culture model system for analyses of some of the rapid excitatory effects of NGF on primary afferent nociceptive neurons that can occur within a few min after application of low concentrations of NGF. This technique may facilitate studies of physiological factors that modulate the efficacy of NGF receptor-mediated functions and may provide a useful method for analyses of possible G-protein-linked signal transduction mechanisms (other than Gs and Gi) that may be associated with NGF receptors (Meakin and Shooter, 1992) .
